Results 231 to 240 of about 273,215 (316)

Robot-assisted Kidney Transplantation from Deceased Donor: The European Experience. [PDF]

open access: yesEur Urol Open Sci
Prudhomme T   +19 more
europepmc   +1 more source

CADAVERIC KIDNEY TRANSPLANTATION IN A PATIENT WITH DONOR-SPECIFIC ANTILEUKOCYTE CYTOTOXIC ANTIBODIES

open access: bronze, 1971
Ramon Patel   +5 more
openalex   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić   +4 more
wiley   +1 more source

Monitoring of Allograft Adaptation After Kidney Transplantation in Pediatric Patients by Targeted Plasma Metabolomics. [PDF]

open access: yesInt J Mol Sci
Klawitter J   +9 more
europepmc   +1 more source

Effectiveness and safety of combining thiazides with loop diuretics vs. loop diuretics monotherapy in patients with acute decompensated heart failure: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study investigated factors associated with and outcomes of combined loop diuretics with hydrochlorothiazide (HCTZ) for acute decompensated heart failure (ADHF). Methods In this retrospective study, adults hospitalized for ADHF and who received intravenous loop diuretics between January 2016 and March 2023 were enrolled.
Chia‐Chen Hsu   +6 more
wiley   +1 more source

An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon‐like peptide‐1 and glucagon receptor in healthy subjects

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Glucagon‐like peptide‐1 (GLP‐1) and glucagon dual receptor agonists are in clinical development for a range of metabolic conditions, including type 2 diabetes and obesity. The cardiovascular actions at these receptors are well studied, but less is known about their combination.
James Goodman   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy